Comparison of oral piracetam and oral batahistine in treatment of acute vertigo
Phase 3
- Conditions
- Disorders of vestibular function.Disorders of vestibular function
- Registration Number
- IRCT2016011921063N3
- Lead Sponsor
- Shahid Beheshti University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 96
Inclusion Criteria
Patients with acute vertigo who are discharged from the ED.
Exclusion criteria:
Age <18 years ; Prior sensitivity to piracetam or betahistin ; Using other drugs that potentially improve vertigo (antihistamines, anticholinergics, bezodiazepines, ...) ; Peptic ulcer disease history ; Pheochromoytoma disease ; Patients who are not consent to participate in the study
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Vertigo severity. Timepoint: 7 days after treatment. Method of measurement: NRS.
- Secondary Outcome Measures
Name Time Method ausea intensity. Timepoint: 7 days after treatment. Method of measurement: NRS.;Fatigue intensity. Timepoint: 7 days after treatment. Method of measurement: NRS.;Adverse events. Timepoint: 7 days after treatment. Method of measurement: Adverse event name.